Home > Publications database > Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas. > print

001     285005
005     20240229155059.0
024 7 _ |a 10.1016/j.xcrm.2023.101249
|2 doi
024 7 _ |a pmid:37883975
|2 pmid
024 7 _ |a altmetric:155773787
|2 altmetric
037 _ _ |a DKFZ-2023-02178
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Blanco-Carmona, Enrique
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas.
260 _ _ |a Maryland Heights, MO
|c 2023
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1701266327_7708
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B062#LA:B320# / 2023 Nov 21;4(11):101249
520 _ _ |a The isocitrate dehydrogenase (IDH) gene is recurrently mutated in adult diffuse gliomas. IDH-mutant gliomas are categorized into oligodendrogliomas and astrocytomas, each with unique pathological features. Here, we use single-nucleus RNA and ATAC sequencing to compare the molecular heterogeneity of these glioma subtypes. In addition to astrocyte-like, oligodendrocyte progenitor-like, and cycling tumor subpopulations, a tumor population enriched for ribosomal genes and translation elongation factors is primarily present in oligodendrogliomas. Longitudinal analysis of astrocytomas indicates that the proportion of tumor subpopulations remains stable in recurrent tumors. Analysis of tumor-associated microglia/macrophages (TAMs) reveals significant differences between oligodendrogliomas, with astrocytomas harboring inflammatory TAMs expressing phosphorylated STAT1, as confirmed by immunohistochemistry. Furthermore, inferred receptor-ligand interactions between tumor subpopulations and TAMs may contribute to TAM state diversity. Overall, our study sheds light on distinct tumor populations, TAM heterogeneity, TAM-tumor interactions in IDH-mutant glioma subtypes, and the relative stability of tumor subpopulations in recurrent astrocytomas.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a IDH mutation
|2 Other
650 _ 7 |a astrocytoma
|2 Other
650 _ 7 |a bone-marrow-derived macrophages
|2 Other
650 _ 7 |a glioma
|2 Other
650 _ 7 |a microglia
|2 Other
650 _ 7 |a oligodendroglioma
|2 Other
650 _ 7 |a recurrent glioma
|2 Other
650 _ 7 |a snATAC-seq
|2 Other
650 _ 7 |a snRNA-seq
|2 Other
650 _ 7 |a tumor microenvironment
|2 Other
700 1 _ |a Narayanan, Ashwin
|b 1
700 1 _ |a Hernandez, Inmaculada
|b 2
700 1 _ |a Nieto, Juan C
|b 3
700 1 _ |a Elosua-Bayes, Marc
|b 4
700 1 _ |a Sun, Xueyuan
|0 P:(DE-He78)1aaab73f118f58d5448020b6034d607a
|b 5
|u dkfz
700 1 _ |a Schmidt, Claudia
|0 P:(DE-He78)2a599a43bd0b5910c80edb288d8da3e5
|b 6
|u dkfz
700 1 _ |a Pamir, Necmettin
|b 7
700 1 _ |a Özduman, Koray
|b 8
700 1 _ |a Herold-Mende, Christel
|b 9
700 1 _ |a Pagani, Francesca
|b 10
700 1 _ |a Cominelli, Manuela
|b 11
700 1 _ |a Taranda, Julian
|0 P:(DE-He78)b7bbfa7c998d298484f881999928daa4
|b 12
|u dkfz
700 1 _ |a Wick, Wolfgang
|0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
|b 13
|u dkfz
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 14
|u dkfz
700 1 _ |a Poliani, Pietro Luigi
|b 15
700 1 _ |a Rehli, Michael
|b 16
700 1 _ |a Schlesner, Matthias
|b 17
700 1 _ |a Heyn, Holger
|b 18
700 1 _ |a Turcan, Sevin
|0 P:(DE-He78)7f4df6a9e19a7687f718e557ec4a9a6b
|b 19
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.xcrm.2023.101249
|g p. 101249 -
|0 PERI:(DE-600)3019420-9
|n 11
|p 101249
|t Cell reports / Medicine
|v 4
|y 2023
|x 2666-3791
909 C O |p VDB
|o oai:inrepo02.dkfz.de:285005
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)1aaab73f118f58d5448020b6034d607a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)2a599a43bd0b5910c80edb288d8da3e5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)b7bbfa7c998d298484f881999928daa4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)7f4df6a9e19a7687f718e557ec4a9a6b
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2023
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL REP MED : 2022
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T14:51:29Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T14:51:29Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T14:51:29Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-22
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-22
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b CELL REP MED : 2022
|d 2023-08-22
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-22
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-22
920 2 _ |0 I:(DE-He78)B320-20160331
|k B320
|l KKE Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)W210-20160331
|k W210
|l Lichtmikroskopie
|x 2
920 1 _ |0 I:(DE-He78)B320-20160331
|k B320
|l KKE Neuroonkologie
|x 3
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 4
920 0 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)W210-20160331
980 _ _ |a I:(DE-He78)B320-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21